Disease Studies


At PrecisionLife we’re taking precision medicine beyond cancer and rare disease into chronic diseases, identifying new options for unmet medical needs, lowering the costs of delivering care, and ensuring patients live their best possible lives.

We’re working with leading healthcare organizations across the world to provide a deeper understanding of disease biology using large-scale patient and real-world evidence datasets.

Our high resolution patient stratification platform identifies the drivers of patients’ risk, their likely disease trajectory and drug responses more accurately to help personalize the treatment and management of chronic disease.

Revealing the drivers of chronic diseases

Complex diseases like dementia, COPD, cardiovascular or metabolic disease usually don’t have simple, single gene explanations. Their underlying genetic, epidemiological and environmental drivers are complex, with many factors acting together. This means that existing single variant genetic analysis approaches used in cancer and rare diseases only scratch the surface of the varied biology of complex chronic diseases. They often fail to reveal how different factors affect different patient sub-groups.

At PrecisionLife we look deeper, analyzing combinations of multiple genetic variants, clinical and epidemiological features to identify clinically relevant patient sub-groups, and explain why some have higher disease risks or respond to drugs differently. These unique disease insights enable targeted approaches to care, based on knowing which biological drivers are relevant to a patient.

The benefits of our approach

Conditions such as diabetes, cardiovascular disease, dementia, immune disorders and respiratory diseases are hugely expensive, complex diseases that all require more personalized diagnosis and treatment options:

  • In type-II diabetes, 80% of the $500 billion spent in the US alone on patient care goes on managing complications such as renal failure, neuropathy, cardiovascular disease and amputations. We are building models that predict which complications a patient is likely to experience.
  • In asthma, 35% of patients do not respond to new biologic medicines targeting T2 (eosinophilic) mechanisms. We have identified biomarker signatures to predict those patients and are exploring new targets to give them better therapeutic options.
  • In neuropsychiatric diseases, the socioeconomic burden is huge, but correctly targeting treatment options to patients is very hard. We are helping marry potential treatment options to patient sub-groups, even for those who do not respond to current therapies of last resort.

Understanding which interventions might prevent future complications, and which treatments will effectively manage a patients’ disease promises to reduce the cost of care and improve patient outcomes.

With deeper insights into disease outcomes and therapy response we help clinicians to improve their at-risk patients’ long-term care and wellness with appropriate treatment and lifestyle choices.

Our approach

What we deliver

Our combinatorial analytics and Combinatorial Risk Score platforms enable high resolution stratification of chronic disease populations and more accurate prediction of the disease trajectories and effective clinical intervention strategies for different patient sub-groups.

Our disease insights, risk scores and personalized decision support tools enable healthcare organizations to deliver personalization at scale, improving population health management, lifestyle recommendations and treatment selection by classifying patients more accurately.

PrecisionLife® platform overview

Our revolutionary platform applies our proprietary mathematical framework and AI techniques to population-scale genomic, clinical and patient health datasets.

We use our platform to rapidly find all the combinations of genomic, phenotypic and clinical features that define disease risk, prognosis and therapy response in a complex disease population. This enables:

  • deeper understanding of the biology of complex diseases
  • more precise patient stratification
  • identification and validation of novel targets for unmet medical needs
  • systematic analysis of drug repurposing opportunities
  • better, more personalized risk scores for complex diseases
  • clinical decision support tools for guiding precision medicine


How we work with you

We work with healthcare organizations through collaborative research programs where a specific disease population is selected for in-depth analysis to identify new insights around disease drivers, stratification options and predictive models. We can then help build tools to use these insights in the context of personalized disease prevention and intervention.

We usually bring our PrecisionLife analysis platform and data scientists to your clinical population datasets, but we can also identify suitable external patient datasets to inform our approach.

Contact us

Disease Studies

Read all Disease Studies
Disease Studies

Type-II Diabetes Complications

We built combinatorial risk scores that predict which type of complications a type-II diabetes patient is likely to experience.

Read more
Disease Studies


We stratified patients from UK Biobank and via combinatorial analysis identified 345 protein-coding genes strongly associated with disease risk.

Read more

Contact us

If you have any questions or would like to speak to us in terms of potential collaborations or partnership opportunities, please get in touch using the form below or email info@precisionlife.com and we will get back to you as soon as we can. Note that our Privacy Policy and Terms & Conditions apply.


Unit 8b Bankside
Hanborough Business Park
Long Hanborough, OX29 8LJ


1 Broadway Fl 14
MA 02142-1187


Agern Allé 3


Chmielna 73m
00-801 Warszawa